Scarica l'app Stockscreener
283.34
11.75%
29.79
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$253.54
Aprire:
$261.82
Volume 24 ore:
3.11M
Relative Volume:
4.49
Capitalizzazione di mercato:
$36.68B
Reddito:
$2.25B
Utile/perdita netta:
$-278.16M
Rapporto P/E:
-130.57
EPS:
-2.17
Flusso di cassa netto:
$-42.59M
1 W Prestazione:
+17.20%
1M Prestazione:
+13.07%
6M Prestazione:
+3.45%
1 anno Prestazione:
+93.25%
Intervallo 1D:
$261.00
$289.44
Intervallo di 1 settimana:
$240.94
$289.44
Portata 52W:
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
283.34 | 36.68B | 2.25B | -278.16M | -42.59M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.20 | 129.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
658.48 | 71.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
615.02 | 37.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
251.98 | 27.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Alnylam Stock Jumps After the FDA Approves Its Heart Drug - The Wall Street Journal
Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster (NASDAQ:ALNY) - Seeking Alpha
U.S. Markets Moved Upward Friday; Alnylam Pharmaceuticals Climbed Highest - Barron's
Buy, Sell, Or Hold Alnylam Stock At $280? - Forbes
Check Out What Whales Are Doing With ALNY - Benzinga
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - Yahoo Finance
Alnylam Pharma Stock (ALNY) Rockets on FDA Drug Approval - TipRanks
Alnylam Drug Approval Brings Cardiomyopathy Competition to Pfizer, BridgeBio Pharma - MedCity News
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy - Yahoo Finance
Alnylam jumps as expanded US approval for heart disease drug fuels growth prospects - MSN
Alnylam prices heart drug at premium to rivals - BioPharma Dive
Alnylam Wins Expanded Heart Drug Approval, Challenging Pfizer - MSN
Alnylam's Amvuttra Gains Expanded US Approval for Heart ConditionNews and Statistics - IndexBox, Inc.
BofA Securities Raises Price Target on Alnylam Pharmaceuticals to $325 From $302, Keeps Buy Rating - Marketscreener.com
Alnylam Heart Drug Approval Sets Up Challenge With Pfizer - Yahoo Finance
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps - Benzinga
Alnylam Expanded Heart Drug Approval Sets Up Pfizer Challenge - MSN
Sector Update: Health Care -March 21, 2025 at 09:20 am EDT - Marketscreener.com
Sector Update: Health Care - TradingView
RBC Adjusts Price Target on Alnylam Pharmaceuticals to $330 From $310, Maintains Outperform Rating - Marketscreener.com
Alnylam scores a first with FDA nod for Amvuttra in ATTR-CM - The Pharma Letter
Alnylam shares rise on expanded heart drug approval -March 21, 2025 at 07:32 am EDT - Marketscreener.com
Alnylam stock rises after FDA nod for AMVUTTRA By Investing.com - Investing.com Canada
Alnylam joins three-way contest in ATTR cardiomyopathy - pharmaphorum
Alnylam’s SWOT analysis: biotechnology stock poised for growth amid ATTR-CM market expansion - Investing.com
Alnylam Pharmaceuticals Recieives US FDA Approval for ATTR-CM Drug -March 21, 2025 at 03:59 am EDT - Marketscreener.com
Alnylam drug gets long-awaited FDA approval in deadly heart disease - BioPharma Dive
FDA Approves Alnylam’s Vutrisiran for the Treatment of ATTR Amyloidosis With Cardiomyopathy - CGTLive™
Alnylam Joins Competitive ATTR-CM Market With Amvuttra Approval - Citeline News & Insights
US FDA expands approval for Alnylam's drug to treat rare heart disease - Reuters
Alnylam wins FDA approval for rare heart disease drug - The Business Journals
FDA approves first dual-action treatment for ATTR amyloidosis - Investing.com India
Amvuttra’s label expansion lifts Alnylam toward five-year goals - BioCentury
US FDA expands approval for Alnylam's drug to treat rare heart disease -March 20, 2025 at 06:04 pm EDT - Marketscreener.com
US FDA approves Alnylam's drug for rare heart condition - Marketscreener.com
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran) -March 20, 2025 at 05:57 pm EDT - Marketscreener.com
US FDA approves Alnylam's drug for rare heart condition -March 20, 2025 at 05:56 pm EDT - Marketscreener.com
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) - Business Wire
Free genetic testing for AHP offered by Alnylam Act in US, Canada - Porphyria News
Alnylam at Stifel’s 2025 CNS Forum: Advances in RNAi for Neurological Diseases - Investing.com
Alnylam Pharmaceuticals To Present At Stifel 2025 Virtual CNS Forum; Webcast At 3:00 PM ET - Nasdaq
Arbor raises $74M amid genetic medicine’s funding slump - BioPharma Dive
RNA Therapies Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approval, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight - The Globe and Mail
Alnylam’s Amvuttra Expected to Make Three in Crowded ATTR-CM Space - BioSpace
How Do Investors Really Feel About Alnylam Pharmaceuticals? - Benzinga
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum? - Nasdaq
Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Victory Capital Management Inc. - Defense World
PreventionGenetics Assumes the Management of Sponsored Genetic Testing Program for Three Rare Genetic Diseases: Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1 & Hereditary ATTR Amyloidosis - BioSpace
Antisense Oligonucleotides Market reached US$ 2,985.97 - openPR
Alnylam Pharmaceuticals’ SWOT analysis: strong data bolsters $8B amvuttra potential - Investing.com
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.32%
4.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):